Tentt

RAPT Therapeutics Acquired by GSK — Healthcare M&A

Announced
HealthcareMerger

Deal Summary

GSK entered a definitive agreement to acquire RAPT Therapeutics for $2.2B, including ozureprubart, an anti-IgE antibody in phase IIb for food allergy prophylaxis.

Key Details

Transaction
GSK acquires RAPT Therapeutics
Deal Size
Over $100M
Reported Value
$2.2 Billion

Source

Read full article on news.google.com

via GN - definitive agreement acquisition · January 20, 2026

Related Deals